Glycated Hemoglobin Detection Service
Glycated hemoglobin is a product formed by the non-enzymatic glycosylation reaction between hemoglobin in red blood cells and carbohydrates in serum. It has a stable structure and a long life span, which can reflect the blood glucose status of patients in the past three months. Therefore, it is a biomarker commonly used to monitor the blood glucose control of diabetic patients. Creative BioMart Biomarker offers sensitive and fast testing service for glycated hemoglobin, ensuring high detection accuracy, reproducibility and efficiency.
Introduction
Hemoglobin is a special protein that transports oxygen in red blood cells and is composed of globin and heme. The amino terminus of the hemoglobin beta chain is capable of reversible reaction with glucose to form an unstable Schiff base, and Schiff base undergoes a conformational rearrangement to produce an Amadori product, which has a stable ketamine bond. The Amadori product then forms advanced glycation end products (AGEs). There are many types of hemoglobin, including HbA1a, HbA1b, and HbA1c, which are classified according to different types of carbohydrates attached to proteins. HbA1c is structurally stable and accounts for about 70%, and is often used as a test subject. The lifespan of glycated hemoglobin is about 90-120 days, and the rate of glycated hemoglobin formation is directly proportional to the concentration of glucose, that is, the concentration of glycated hemoglobin can reflect the average blood glucose level over a period of time. Therefore, glycated hemoglobin is a biomarker used to assess the long-term blood glucose status of the patients. Based on the characteristics of glycated hemoglobin, it is often used to monitor glycemic control in diabetic patients. In addition, glycated hemoglobin can be used for early screening and diagnosis of diabetes, and has certain clinical significance for the adjustment of treatment options for diabetes. Compared with other partial clinical diagnosis methods of diabetes, the detection of glycosylated hemoglobin may be more conducive to the early detection and diagnosis of diabetes, thereby conducive to early control of the disease. Glycated hemoglobin can also be used to assess the risk of diabetes complications. For example, glycated hemoglobin can be used as a predictor of universal retinopathy. The increase of glycated hemoglobin is also related to other diseases such as chronic kidney disease.
Figure 1. Protein structure of N terminus of the β chain of HbA1c and Hb through PyMOL simulation (Dong, 2019)
Application of Glycated Hemoglobin Detection
Plasma and serum glycated hemoglobin levels can be studied as a biomarker in researches related to type 2 diabetes mellitus, inflammation, etc.
Our Advantages
- Guarantee high accuracy and sensitivity for glycated hemoglobin detection
- Ensure high repeatability of glycated hemoglobin detection
- Short turn-around time of detection service
- Competitive price in the market of glycated hemoglobin detection services
- Multiple technology platforms for glycated hemoglobin test services (ELISA, CLIA, etc.)
- Accept a wide range of sample types (plasma, serum, cell lysates, etc.)
Workflow of Glycated Hemoglobin Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the glycated hemoglobin detection procedure to ensure accurately quantify the level of glycated hemoglobin in each sample.
At Creative BioMart Biomarker, we offer glycated hemoglobin testing service that ensuring the sensitivity and specificity of test results. You can also talk to our experts according to your certain requirement, and we will determine the final detection scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Dong, P.T.; et al. Label-free quantitation of glycated hemoglobin in single red blood cells by transient absorption microscopy and phasor analysis. Science Advances. 2019, 5(5): eaav0561.
- Ikeda, M.; Shimazawa, R. Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. Journal of General and Family Medicine. 2019, 20(4): 129-138.
- Hörber, S.; et al. Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnology Advances. 2019.
